tri1

TRi-1 is irreversible inhibitor of cytosolic thioredoxin reductase 1 (TXNRD1), with an IC50 of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy

1,2,3-Tri-10(Z)-undecenoyl glycerol is a triglyceride composed of 10-undecenoic acid esterified at the sn-1, sn-2, and sn-3 positions.

1,2,3-Tri-13(E)-docosenoyl glycerol, a triacylglycerol featuring 13(E)-docosenoic acid at the \(sn-1\), \(sn-2\), and \(sn-3\) positions, transiently elevates heart triglyceride levels in weanling rats when administered as 15% of a calcium-deficient diet, with levels returning to baseline after 28 days.

1,2,3-Tri-11(Z)-eicosenoyl glycerol, a triacylglycerol with 11(Z)-eicosenoic acid at the sn-1,sn-2, and sn-3 positions, serves as an internal standard for quantifying triacylglycerols in seed and olive oils.

Tri-11(E)-eicosenoin is a lipid utilized in the formulation of lipid nanoparticles (LNP) for drug delivery applications.

Tri-11(Z),14(Z),17(Z)-eicosatrienoin is a lipid utilized in formulating lipid nanoparticles (LNPs) for drug delivery purposes.

Tri-11(Z)-octadecenoin is a lipid used in the formulation of lipid nanoparticles (LNP) for drug delivery applications.

Tri-10(Z)-nonadecenoin is a lipid utilized in the preparation of lipid nanoparticles (LNP) for drug delivery applications.

Tri-11(Z),14(Z)-eicosadienoin is a lipid utilized in the formulation of lipid nanoparticles (LNP) for drug delivery.

Tri-10(Z)-pentadecenoin (1,2,3-Tri-10(Z)-pentadecenoyl glycerol) is a triglyceride in which the sn-1, sn-2, and sn-3 positions are all esterified with 10(Z)-pentadecenoic acid.